The Clinical Significance of Aurora-A/STK15/BTAK Expression in Human Esophageal Squamous Cell Carcinoma
Overview
Authors
Affiliations
Purpose: Aurora-A/STK15/BTAK (Aurora-A) encodes a Serine/Threonine kinase associated with chromosomal distribution, and its up-regulation induces chromosomal instability thereby leading to aneuploidy and cell transformation in several types of cancer. In this study, we investigated the role of Aurora-A in human esophageal squamous cell carcinoma (ESCC).
Experimental Design: The expression levels of Aurora-A mRNA were compared in 33 ESCC tissues with that in corresponding normal esophageal epithelium by semiquantitative reverse transcription-PCR, and the distribution patterns and expression levels of Aurora-A protein were immunohistochemically investigated in the ESCC tumors of 142 patients. The results were then separately compared with the clinicopathologic findings of the patients, and the expression of Aurora-A was examined in nine ESCC cell lines and a normal esophageal epithelial cell line using Western blot analysis.
Results: The up-regulation of Aurora-A mRNA was found in 30% (10 of 33) of the tumors by semiquantitative reverse transcription-PCR, and protein up-regulation was found in 53% (75 of 142) of the patients by immunohistochemistry. mRNA and protein up-regulation of Aurora-A were correlated with distant lymph node metastasis (P = 0.05 and P = 0.04, respectively), and patients with Aurora-A mRNA or protein up-regulation had a poorer prognosis (P = 0.003 and P = 0.0009, respectively). Furthermore, multivariate analysis revealed that up-regulation of the Aurora-A protein was an independent prognostic factor. In addition, Aurora-A expression in all ESCC cell lines was higher than that in a normal esophageal epithelial cell line.
Conclusions: The up-regulation of Aurora-A expression may reflect the malignant behavior of ESCC and may prove useful information as a prognostic factor for ESCC patients.
Knowledge mapping of AURKA in Oncology:An advanced Bibliometric analysis (1998-2023).
Zhou Q, Tao C, Yuan J, Pan F, Wang R Heliyon. 2024; 10(11):e31945.
PMID: 38912486 PMC: 11190563. DOI: 10.1016/j.heliyon.2024.e31945.
Chen M, Zhu H, Li J, Luo D, Zhang J, Liu W Ann Med. 2024; 56(1):2282184.
PMID: 38738386 PMC: 11095293. DOI: 10.1080/07853890.2023.2282184.
Aurora Kinases as Therapeutic Targets in Head and Neck Cancer.
Nguyen T, Silva F, Golemis E Cancer J. 2022; 28(5):387-400.
PMID: 36165728 PMC: 9836054. DOI: 10.1097/PPO.0000000000000614.
Bagul C, Rao G, Veena I, Kulkarni R, Tamboli J, Akunuri R Mol Divers. 2022; 27(3):1185-1202.
PMID: 36114912 DOI: 10.1007/s11030-022-10481-x.
Camuzi D, Aguirre Buexm L, Lourenco S, Grazziotin R, Guaraldi S, Valverde P Int J Mol Sci. 2022; 23(14).
PMID: 35887149 PMC: 9316635. DOI: 10.3390/ijms23147801.